Pipeline

Our macrocyclic platform has fueled our pipeline of highly potent, proprietary kinase inhibitors that are structurally different from many existing kinase inhibitors and may address the key issues of emerging treatment resistance and toxicities that limit duration of treatment. We hold global development and commercialization rights to all of our drug candidates.

pipeline-scientist

Candidate Selection

IND Enabling Studies

Phase 1

Phase 2

Phase 3¹

Upcoming
Milestones

(ROS1/TRK)

Repotrectinib

(ROS1/TRK)

Repotrectinib

ROS1+ advanced NSCLC in TKI-naïve patients

ROS1+ advanced NSCLC in platinum based chemo- and TKI-pretreated patients

NTRK+ advanced solid tumors in TKI-naïve patients

NTRK+ advanced solid tumors in TKI-pretreated patients

TRIDENT-1
Registrational
cohorts

Current Phase

Phase 1

TRIDENT-1
Registrational
cohorts

Initiated registrational Phase 2 portion in 2H 2019

ROS1+ advanced NSCLC TKI-pretreated w/o prior chemo

Current Phase

Phase 1

Non-registrational cohort of TRIDENT-1

Repotrectinib in pediatric advanced solid tumors

Current Phase

IND Enabling Studies

Initiated trial in 2H 2019

Repotrectinib combinations

Current Phase

IND Enabling Studies

Trial design in development

(MET/CSF1R/SRC)

TPX-0022

(MET/CSF1R/SRC)

TPX-0022

MET+ advanced solid tumor patients

Current Phase

Phase 1

Initiated trial in 2H 2019

(RET/SRC)

TPX-0046

(RET/SRC)

TPX-0046

RET+ advanced solid tumor patients

Current Phase

IND Enabling Studies

Initiated trial in 2H 2019

(ALK)

TPX-0131

(ALK)

TPX-0131

ALK+ advanced NSCLC

Not required for Phase 2 registrational clinical trials

Management
Board of Directors

Repotrectinib
TPX-0022
TPX-0046
ALK Inhibitor

OUR SCIENCE

Our Approach
Addressing Resistance
Publications

CLINICAL TRIALS

TRIDENT-1
Compassionate Use

Press Releases
Publications

Mission and Values
Our Culture
Opportunities

Copyright © 2020 Turning Point Therapeutics, Inc. | All Rights Reserved | Terms of Use | Privacy Policy Statement